Clinical Trial

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 17, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, multicenter Phase II clinical trial of SHR-A1811 for injection in patients with HER2-expressing recurrent or metastatic cervical cancer who have failed prior systemic therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-26.
Status change: Not Yet Recruiting → Recruiting 2025-11-13
Trial Details
NCT Number NCT07051486
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Recurrent or Metastatic Cervical Cancer
Enrollment 60 participants
Start Date 2025-10-11
Primary Completion 2026-02 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-11-17